125 related articles for article (PubMed ID: 17354103)
1. High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a.
Meng J; Yan Z; Wu J; Li L; Xue X; Li M; Li W; Hao Q; Wan Y; Qin X; Zhang C; You Y; Han W; Zhang Y
Cytotherapy; 2007; 9(1):60-8. PubMed ID: 17354103
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR.
Zhang B; Gao B; Dong S; Zhang Y; Wu Y
Regul Toxicol Pharmacol; 2011 Jun; 60(1):73-8. PubMed ID: 21338646
[TBL] [Abstract][Full Text] [Related]
3. [SOCS1 knockdown sensitize anti-tumor activity of IFN-alpha2a-NGR].
Huang QC; Lei XY; Liu Y; Sui WJ; Li S; Zhang YQ; Yan Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 May; 26(5):412-5. PubMed ID: 20423643
[TBL] [Abstract][Full Text] [Related]
4. Expression, refolding, and characterization of GFE peptide-fused human interferon-alpha2a in Escherichia coli.
Yan Z; Lu L; Shi J; Bao C; Han W; Wu Y; Zhang Y
Appl Biochem Biotechnol; 2006 May; 133(2):149-62. PubMed ID: 16702607
[TBL] [Abstract][Full Text] [Related]
5. Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
[TBL] [Abstract][Full Text] [Related]
6. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
7. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional characterization of tumor-targeted fusion protein composed of NGR peptide and 15-kDa actin fragment.
Lei H; Cao P; Miao G; Lin Z; Diao Z
Appl Biochem Biotechnol; 2010 Oct; 162(4):988-95. PubMed ID: 20119635
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro.
Wen Z; Jia Q; Kang X; Lou Y; Zou L; Yang J; Gao J; Han L; Li X
Anticancer Drugs; 2017 Jan; 28(1):31-39. PubMed ID: 27759573
[TBL] [Abstract][Full Text] [Related]
10. Recombinant IFN-α2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-α2a in vivo and in vitro.
Li W; Hao Q; He L; Meng J; Li M; Xue X; Zhang C; Li H; Zhang W; Zhang Y
Cytotechnology; 2015 Dec; 67(6):1039-50. PubMed ID: 24897998
[TBL] [Abstract][Full Text] [Related]
11. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
12. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of a novel bioactive IFN-alpha2b/CM4 fusion protein in Escherichia coli.
Li NN; Liu P; Chen SJ; Lin QP; Zhou LF; Zhang SQ
Microbiol Res; 2010 Feb; 165(2):116-21. PubMed ID: 19246180
[TBL] [Abstract][Full Text] [Related]
14. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
[TBL] [Abstract][Full Text] [Related]
15. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
16. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
[TBL] [Abstract][Full Text] [Related]
17. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
18. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy.
Xu K; Lee F; Gao SJ; Chung JE; Yano H; Kurisawa M
J Control Release; 2013 Mar; 166(3):203-10. PubMed ID: 23328125
[TBL] [Abstract][Full Text] [Related]
19. [Up-regulation of thymidine phosphorylase and anti-angiogenesis by interferon alpha in human hepatocellular carcinoma cell line and xenograft].
Xiao YS; Zhou J; Tang ZY; Fan J; Wu ZQ; Liu YK; Ye SL; Shen ZZ; Xue Q; Zhao Y
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3205-9. PubMed ID: 16405841
[TBL] [Abstract][Full Text] [Related]
20. Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.
Gasparri AM; Jachetti E; Colombo B; Sacchi A; Curnis F; Rizzardi GP; Traversari C; Bellone M; Corti A
Mol Cancer Ther; 2008 Dec; 7(12):3859-66. PubMed ID: 19074858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
